Myocardial Injury for COVID-19 Even in Young Patients with Mild Symptoms
Most young COVID-19 patients not requiring hospitalization showed abnormal cardiac magnetic resonance imaging (CMR) beyond two months after diagnosis.
Read more HERE
Infarction, Stroke and Aortic Emergency Syndromes in the Shadow of the Pandemic
The coronavirus pandemic has had a negative impact on the most pressing cardio and neurological emergencies, such as strokes or aortic dissection. These emergencies are normally treated in high complexity centers, which is why it is relatively simple to analyze the number of transfers before and after the pandemic.
Read more HERE
Rapid Drop of Antibodies in Mild COVID-19 patients
A fast drop in COVID-19 antibodies in mild patients triggers the alarm for protection against the new virus.
Read more HERE
When and How Could Dexamethasone Be Useful in a COVID-19 Infection?
More details have emerged on the group of COVID-19 patients who received dexamethasone in the RECOVERY trial.
Read more HERE
COVID-19 PE: Nontraditional Risk Factors?
Risk factors for pulmonary embolism (PE) among patients with the new coronavirus are different from those traditionally observed.
Read more HERE
Vasculitis, Thrombosis and Angiogenesis: Covid-19´s Unique Patters
In this small, yet interesting series, we observe angiogenesis could differentiate pulmonary physiopathology by Covid-19 vs. from viral infections of similar severity (such as influenza).
Read more HERE
This document emerges from the assembly of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the Acute Cardiovascular Care Association (ACVC).
Read more HERE
EuroPCR 2020 | Sudden Death Increase Two to Three Times While MI Rate Falls
The number of sudden deaths reported around the world is on the rise in Covid-19 times. These deaths are caused either by the virus and its capacity to produce lethal arrhythmias or by the fact that patients are staying away from hospitals and are not being examined.
Read more HERE
Myocardial Injury in One Third of COVID-19 Patients
Roughly one third of patients hospitalized for COVID-19 have some degree of myocardial injury and this comes hand in hand with increased mortality compared against patients with no troponin elevation.
Read more HERE
Estimating the Risk of Infection for Healthcare Personnel
Roughly one out of every 100 healthcare workers at hospitals receiving COVID-19 patients become infected. Statistics are not uniform for all corners of earth, and they do not indicate that being on the front line necessarily entails higher risk.
Read more HERE
Priorities in the Cath Lab to Escape COVID-19 Tsunami
The pandemic tsunami of COVID-19 has hit all cath lab services, especially those performing primary PCI. Passively waiting for the first patient suspected of infection only to improvise in the early hours means heading for disaster.
Read more HERE
Covid-19 and Unaccounted Collateral Damage
Dr Metzler and collaborators carried out a retrospective search to find out the impact of the Covid-19 pandemic on diagnosis and treatment of acute coronary syndromes during March 2020 in Austria. Basically, they tried to account for the collateral damage we all imagine, but no government reports.
Read more HERE
Cardiovascular Sequelae Associated with COVID-19
Myocardial injury, as defined by an increased troponin level, can occur due to both ischemic and nonischemic processes. Myocarditis would be an example of a nonischemic event.
Read more HERE
Always in Favor of Primary Angioplasty, Even in the Pandemic Era
Compared with fibrinolytic therapy, reperfusion through primary angioplasty is more reliable and durable, and has less complications. This results in a higher net clinical benefit, both in terms of mortality and of reinfarction and bleeding.
Read more HERE
In Favor of the Use of Thrombolytics in Pandemic Times
The Covid-19 pandemic has dramatically altered reperfusion therapy access in patients undergoing ST elevation MI. In these adverse times, it seems prudent to reassess the reperfusion algorithm.
Read more HERE
Thrombosis and Thromboembolism Associated with COVID-19
Coronavirus disease 2019 (COVID-19) is a viral respiratory illness that can cause a severe acute respiratory syndrome (SARS-CoV-2), predisposing patients to thrombosis (both in veins and arteries) due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis.
Read more HERE
How is the Pandemic Affecting MI? The Chinese Experience
ST elevation acute myocardial infarction has high mortality and morbidity rates. It is normally treated with primary PCI. The whole system has established very effective protocols to minimize ischemic time from symptom onset to definite treatment in the cath lab.
Read more HERE
ECS Guidelines for COVID-19 Management
One of the first statements in this document points out these are not “regular guidelines” developed after thorough analysis of all the available evidence published since the last update. Instead, they are meant to provide temporary basic management pointers on how to handle different scenarios of cardiac patients in the context of the COVID-19 pandemic.
Read more HERE
ST-Segment Elevation Myocardial Infarction in the Time of COVID-19
This study cites the experience of 6 sites during the first month of the COVID-19 pandemic in New York. All patients included had a confirmed diagnosis of coronavirus infection and also ST-segment elevation on electrocardiography.
Read more HERE
Procedural Rescheduling Criteria in the Pandemic Era
Patients with structural heart disease are at higher risk in the face of the new coronavirus infection due to both advanced age and numerous comorbidities.
Read more HERE
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
